ALX Oncology Taps Biopharma Veteran Jeff Knight as CDO to Drive Late-Stage Pipeline
Event summary
- Jeff Knight joins ALX Oncology as Chief Development and Operating Officer on April 13, 2026.
- Knight brings 30+ years of biopharmaceutical experience, including roles at Crinetics, Poseida, Halozyme, Amgen, and Genentech.
- ALX Oncology anticipates key catalysts in the next 12–18 months for evorpacept and ALX2004 clinical programs.
- Knight will strengthen development capabilities and operational infrastructure for late-stage development and commercialization.
The big picture
ALX Oncology’s appointment of Jeff Knight underscores its push toward late-stage clinical development and commercialization. The move aligns with broader industry trends where biotech firms bolster leadership to navigate complex regulatory and operational challenges. Knight’s extensive experience in advancing oncology programs positions ALX Oncology to strengthen its pipeline and operational infrastructure ahead of critical milestones.
What we're watching
- Pipeline Execution
- How Knight’s leadership will impact the pace of evorpacept and ALX2004 clinical trials.
- Operational Scaling
- Whether ALX Oncology can sustain high-quality execution during its growth phase.
- Commercialization Readiness
- The strategic moves ALX Oncology makes to prepare for late-stage development and potential commercialization.
Related topics